Table 1.
Overview of the included clinical trials of ICIs in HNSCC.
| NCT number | Study type | No. of patients | ICI dose | RR (%) | Median OS (months) |
|---|---|---|---|---|---|
| 02105636 (Checkmate-141) | Randomized phase III | 240 | Nivolumab 3 mg/kg, every 2 weeks | 13.3 | 7.5 |
| 01848834 (Keynote-012) | Phase Ib | 192 | Pembrolizumab 10 mg/kg, every 2 weeks OR Pembrolizumab 200 mg every 3 weeks |
18 | 8 |
| 02252042 (Keynote-040) | Randomized phase III | 247 | Pembrolizumab 200 mg every 3 weeks | 14.6 | 8.4 |
| 02255097 (Keynote-055) | Phase II | 171 | Pembrolizumab 200 mg every 3 weeks | 16 | 8 |
| 01375842 | Phase Ia | 32 | Atezolizumab 15/20 mg/kg every 3 weeks | 21 | 6 |
| 01693562 | Phase I/II | 62 | Durvalumab 10 mg/kg every 2 weeks | 6.5 | 8.4 |
| 02207530 | phase II | 112 | Durvalumab 10 mg/kg every 2 weeks | 16.2 | 7.1 |
| 02319044 | Randomized phase II | 133 | Durvalumab (20 mg/kg every 4 weeks) + tremelimumab (1 mg/kg every 4 weeks) | 7.8 | 7.6 |
| 67 | Durvalumab (10 mg/kg every 2 weeks) | 9.2 | 6 | ||
| 67 | Tremelimumab (10 mg/kg every 4 weeks | 1.6 | 5.5 |
NCT, national clinical trial; ICIs, immune checkpoint inhibitors; RR, response rate; OS, overall survival; HNSCC, head and neck squamous cell carcinoma.